First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results